Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)

  • Gago-Veiga, Ana Beatriz
  • Lopez-Rodriguez, Ana Belen
  • Sanchez Jimenez, Marina
  • Iglesias Rubio, Alvaro
  • Montes, Nuria
  • Camiña Muñiz, Javier
  • Dominguez Gallego, Marta
  • Calle De Miguel, Carlos
  • Latorre, Germán
  • Rodriguez-Vico, Jaime
  • Jaimes, Alex
  • Gomez Garcia, Andrea
  • Urtiaga, Sarai
  • Gonzalez Salaices, Marta
  • Dileone, Michele
  • Gonzalez-García, Nuria
  • Porta-Etessam, Jesús
  • Cuadrado, María-Luz
  • Santos Lasaosa, Sonia
  • Díaz-De-Terán, Javier
  • Portocarrero-Sánchez, Leonardo
  • Casas-Limón, Javier
  • Fernández-Lázaro, Iris
Background: Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for both acute and preventive treatment of episodic migraine. Real-world data on its preventive use remain limited, particularly in patients with multiple prior preventive failures. This study evaluated the effectiveness and tolerability of rimegepant in routine clinical practice, focusing on a highly treatment-resistant population. Methods: We conducted a prospective, multicenter real-world cohort study within the GEMA (GEpants in MigrAine) Project across nine tertiary Headache Units in Spain. Adults initiating rimegepant for migraine prevention were consecutively enrolled and followed for up to 6 months. The primary endpoint was the 3-month change in monthly headache days (MHD). Secondary endpoints included the change in monthly migraine days (MMD), response rates, predictors of response, and tolerability. Baseline characteristics, prior preventive failures, medication overuse, adverse events, and patient-reported outcomes (Headache Impact Test-6 (HIT-6), HADS, and Insomnia Severity Index) were recorded. Results: In total, 150 patients completed 3-month follow-up and 64 reached 6 months. The cohort was predominantly female (85.3%), with 70.7% episodic migraine, a median age of 48 years (interquartile range (IQR) = 39–57), and a median of 6 prior preventive failures (IQR = 4–8), reflecting high treatment resistance. At 3 months, median MHD decreased from 12 to 7.5 and MMD from 10 to 6 (p < 0.05), with significant improvement in HIT-6. Overall, 36% and 43% achieved ≥ 50% reduction in MHD and MMD, respectively (≥ 75%: 15% and 20%). Among patients with 6-month data, further reductions were observed (MHD, 6 days; MMD, 5 days), with ≥ 50% response rates increasing to 48% and 58%. Clinical responders showed greater improvements in anxiety and depressive symptoms. Medication overuse, chronic migraine, and prior exposure to anti-CGRP monoclonal antibodies and onabotulinumtoxinA were independent predictors of poorer outcomes, with response declining with increasing prior anti-CGRP exposure, although a relevant proportion still achieved meaningful benefit. Rimegepant was well tolerated, with predominantly mild adverse events (nausea 13%, constipation 8%) and low discontinuation (7% at 3 months), and with nausea being the most frequent cause. Conclusions: Rimegepant showed meaningful preventive effectiveness and good tolerability in routine clinical practice, including in highly treatment-resistant patients with prior anti-CGRP monoclonal antibody exposure. The response was influenced by baseline disease burden and prior treatment exposure. These findings suggest that earlier use of rimegepant in the treatment course may be associated with greater clinical benefit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

RE-START, Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine

  • Romero del Rincón, Celia|||0000-0002-0339-6616
  • Gonzalez-Martinez, Alicia|||0000-0002-1228-1503
  • Quintas, Sonia|||0000-0003-0622-8228
  • Garcia Azorin, David|||0000-0002-3132-1064
  • Fernández-Lázaro, Iris|||0009-0004-2544-5206
  • Guerrero Peral, Ángel Luis|||0000-0001-7493-6002
  • González Osorio, Yésica|||0000-0003-1461-9798
  • Santos Lasaosa, Sonia|||0000-0002-4141-7705
  • González Oria, Carmen
  • Sánchez Rodríguez, Norberto
  • Iglesias Díez, Fernando
  • Echavarría Íñiguez, Ana|||0000-0001-7038-2911
  • Gil Luque, Sendoa
  • Huerta, Mariano|||0000-0003-0181-5335
  • Campoy Diaz, Sergio|||0000-0002-8135-4139
  • Muñoz-Vendrell, Albert|||0000-0001-8221-865X
  • Lozano Ros, Alberto|||0000-0002-5186-8657
  • Sánchez-Soblechero, Antonio|||0000-0002-7098-8494
  • Velasco Juanes, Fernando
  • Kortazar-Zubizarreta, Izaro|||0000-0002-8107-660X
  • Echeverría, Amaya|||0000-0001-9225-5323
  • Rodríguez-Vico, Jaime|||0000-0001-9360-5444
  • Jaimes Sánchez, Alex
  • Gómez García, Andrea
  • Morollón Sánchez-Mateos, Noemí|||0000-0003-4256-4210
  • Belvís, Roberto|||0000-0002-2137-180X
  • Navarro Pérez, María Pilar|||0000-0001-6370-218X
  • García-Moncó, Juan Carlos
  • Álvarez Escudero, María Rocío
  • Montes, Nuria
  • Gago-Veiga, Ana Beatriz|||0000-0002-0038-3406
Background and purpose: According to the latest European guidelines, discontinuation of monoclonal antibodies against calcitonin gene-related peptide (anti-CGRP MAb) may be considered after 12-18 months of treatment. However, some patients may worsen after discontinuation. In this study, we assessed the response following treatment resumption. Methods: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD. Results: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001). Conclusion: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.